APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Chronic Urticaria Or Hives Drug

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Chronic Urticaria Or Hives Drug Market Outlook and Growth Opportunities 2026

Report ID 173978090426 December 2025195 pages

Choose your research edition.

Industry ResearchChronic Urticaria Or Hives Drug Industry Research Report 2026120 pages · $2,950 USDIndustry Growth & TrendsGlobal Chronic Urticaria Or Hives Drug Industry Growth and Trends Forecast to 2032106 pages · $3,450 USDMarket StructureGlobal Chronic Urticaria Or Hives Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032190 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Chronic Urticaria Or Hives Drug Market Outlook and Growth Opportunities 2026195 pages · $4,250 USDMarket Analysis & ForecastGlobal Chronic Urticaria Or Hives Drug Market Analysis and Forecast 2026-2032193 pages · $4,950 USD

Market perspective

The global Chronic Urticaria Or Hives Drug market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Chronic Urticaria Or Hives Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Chronic Urticaria Or Hives Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Chronic Urticaria Or Hives Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Chronic Urticaria Or Hives Drug market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Chronic Urticaria Or Hives Drug market include Novartis AG, Merck & Co., Inc., AstraZeneca Plc, Panacea Biotec Limited, Mycenax Biotech Inc., Mabtech Limited, J Uriach Y Compania, S.A., GlaxoSmithKline Plc and Genentech, Inc., among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Chronic Urticaria Or Hives Drug market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Chronic Urticaria Or Hives Drug and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Chronic Urticaria Or Hives Drug sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Chronic Urticaria Or Hives Drug market size, projected growth trends, production technologies, key applications, and end-use industries.

Chronic Urticaria Or Hives Drug Segment by Company

Novartis AG

Merck & Co., Inc.

AstraZeneca Plc

Panacea Biotec Limited

Mycenax Biotech Inc.

Mabtech Limited

J Uriach Y Compania, S.A.

GlaxoSmithKline Plc

Genentech, Inc.

Faes Farma, SA

ELORAC, Inc.

Biofrontera AG

Chronic Urticaria Or Hives Drug Segment by Type

BF-Derm-1

GDC-0853

GSK-2646264

Bilastine

Others

Chronic Urticaria Or Hives Drug Segment by Application

Clinic

Hospital

Others

Chronic Urticaria Or Hives Drug Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Chronic Urticaria Or Hives Drug status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Chronic Urticaria Or Hives Drug market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Chronic Urticaria Or Hives Drug significant trends, drivers, influence factors in global and regions.

6. To analyze Chronic Urticaria Or Hives Drug competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Chronic Urticaria Or Hives Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Chronic Urticaria Or Hives Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Chronic Urticaria Or Hives Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Chronic Urticaria Or Hives Drug market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Chronic Urticaria Or Hives Drug industry.

Chapter 3: Detailed analysis of Chronic Urticaria Or Hives Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Chronic Urticaria Or Hives Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Chronic Urticaria Or Hives Drug in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Chronic Urticaria Or Hives Drug Industry Trends Table 2. Chronic Urticaria Or Hives Drug Industry Drivers Table 3. Chronic Urticaria Or Hives Drug Industry Opportunities and Challenges Table 4. Chronic Urticaria Or Hives Drug Industry Restraints Table 5. Global Chronic Urticaria Or Hives Drug Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Chronic Urticaria Or Hives Drug Revenue Share by Company (2021-2026) Table 7. Global Chronic Urticaria Or Hives Drug Sales Volume by Company (W Units) & (2021-2026) Table 8. Global Chronic Urticaria Or Hives Drug Sales Volume Share by Company (2021-2026) Table 9. Global Chronic Urticaria Or Hives Drug Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Chronic Urticaria Or Hives Drug Company Ranking, (2024-2026) & (USD Million) Table 11. Global Chronic Urticaria Or Hives Drug Key Company Manufacturing Base & Headquarters Table 12. Global Chronic Urticaria Or Hives Drug Company, Product Type & Application Table 13. Global Chronic Urticaria Or Hives Drug Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Chronic Urticaria Or Hives Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of BF-Derm-1 Table 18. Significant Companies of GDC-0853 Table 19. Significant Companies of GSK-2646264 Table 20. Significant Companies of Bilastine Table 21. Significant Companies of Others Table 22. Global Chronic Urticaria Or Hives Drug Sales Volume by Type 2021 VS 2025 VS 2032 (W Units) Table 23. Global Chronic Urticaria Or Hives Drug Sales Volume by Type (2021-2026) & (W Units) Table 24. Global Chronic Urticaria Or Hives Drug Sales Volume by Type (2027-2032) & (W Units) Table 25. Global Chronic Urticaria Or Hives Drug Sales Volume Share by Type (2021-2026) Table 26. Global Chronic Urticaria Or Hives Drug Sales Volume Share by Type (2027-2032) Table 27. Global Chronic Urticaria Or Hives Drug Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 28. Global Chronic Urticaria Or Hives Drug Sales Value by Type (2021-2026) & (US$ Million) Table 29. Global Chronic Urticaria Or Hives Drug Sales Value by Type (2027-2032) & (US$ Million) Table 30. Global Chronic Urticaria Or Hives Drug Sales Value Share by Type (2021-2026) Table 31. Global Chronic Urticaria Or Hives Drug Sales Value Share by Type (2027-2032) Table 32. Significant Companies of Clinic Table 33. Significant Companies of Hospital Table 34. Significant Companies of Others Table 35. Global Chronic Urticaria Or Hives Drug Sales Volume by Application 2021 VS 2025 VS 2032 (W Units) Table 36. Global Chronic Urticaria Or Hives Drug Sales Volume by Application (2021-2026) & (W Units) Table 37. Global Chronic Urticaria Or Hives Drug Sales Volume by Application (2027-2032) & (W Units) Table 38. Global Chronic Urticaria Or Hives Drug Sales Volume Share by Application (2021-2026) Table 39. Global Chronic Urticaria Or Hives Drug Sales Volume Share by Application (2027-2032) Table 40. Global Chronic Urticaria Or Hives Drug Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 41. Global Chronic Urticaria Or Hives Drug Sales Value by Application (2021-2026) & (US$ Million) Table 42. Global Chronic Urticaria Or Hives Drug Sales Value by Application (2027-2032) & (US$ Million) Table 43. Global Chronic Urticaria Or Hives Drug Sales Value Share by Application (2021-2026) Table 44. Global Chronic Urticaria Or Hives Drug Sales Value Share by Application (2027-2032) Table 45. Global Chronic Urticaria Or Hives Drug Sales by Region: 2021 VS 2025 VS 2032 (W Units) Table 46. Global Chronic Urticaria Or Hives Drug Sales by Region (2021-2026) & (W Units) Table 47. Global Chronic Urticaria Or Hives Drug Sales Market Share by Region (2021-2026) Table 48. Global Chronic Urticaria Or Hives Drug Sales by Region (2027-2032) & (W Units) Table 49. Global Chronic Urticaria Or Hives Drug Sales Market Share by Region (2027-2032) Table 50. Global Chronic Urticaria Or Hives Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 51. Global Chronic Urticaria Or Hives Drug Sales Value by Region (2021-2026) & (US$ Million) Table 52. Global Chronic Urticaria Or Hives Drug Sales Value Share by Region (2021-2026) Table 53. Global Chronic Urticaria Or Hives Drug Sales Value by Region (2027-2032) & (US$ Million) Table 54. Global Chronic Urticaria Or Hives Drug Sales Value Share by Region (2027-2032) Table 55. Global Chronic Urticaria Or Hives Drug Market Average Price (US$/Unit) by Region (2021-2026) Table 56. Global Chronic Urticaria Or Hives Drug Market Average Price (US$/Unit) by Region (2027-2032) Table 57. Global Chronic Urticaria Or Hives Drug Sales by Country: 2021 VS 2025 VS 2032 (W Units) Table 58. Global Chronic Urticaria Or Hives Drug Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 59. Global Chronic Urticaria Or Hives Drug Sales by Country (2021-2026) & (W Units) Table 60. Global Chronic Urticaria Or Hives Drug Sales Market Share by Country (2021-2026) Table 61. Global Chronic Urticaria Or Hives Drug Sales by Country (2027-2032) & (W Units) Table 62. Global Chronic Urticaria Or Hives Drug Sales Market Share by Country (2027-2032) Table 63. Global Chronic Urticaria Or Hives Drug Sales Value by Country (2021-2026) & (US$ Million) Table 64. Global Chronic Urticaria Or Hives Drug Sales Value Market Share by Country (2021-2026) Table 65. Global Chronic Urticaria Or Hives Drug Sales Value by Country (2027-2032) & (US$ Million) Table 66. Global Chronic Urticaria Or Hives Drug Sales Value Market Share by Country (2027-2032) Table 67. Novartis AG Company Information Table 68. Novartis AG Business Overview Table 69. Novartis AG Chronic Urticaria Or Hives Drug Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 70. Novartis AG Chronic Urticaria Or Hives Drug Product Portfolio Table 71. Novartis AG Recent Development Table 72. Merck & Co., Inc. Company Information Table 73. Merck & Co., Inc. Business Overview Table 74. Merck & Co., Inc. Chronic Urticaria Or Hives Drug Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 75. Merck & Co., Inc. Chronic Urticaria Or Hives Drug Product Portfolio Table 76. Merck & Co., Inc. Recent Development Table 77. AstraZeneca Plc Company Information Table 78. AstraZeneca Plc Business Overview Table 79. AstraZeneca Plc Chronic Urticaria Or Hives Drug Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 80. AstraZeneca Plc Chronic Urticaria Or Hives Drug Product Portfolio Table 81. AstraZeneca Plc Recent Development Table 82. Panacea Biotec Limited Company Information Table 83. Panacea Biotec Limited Business Overview Table 84. Panacea Biotec Limited Chronic Urticaria Or Hives Drug Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 85. Panacea Biotec Limited Chronic Urticaria Or Hives Drug Product Portfolio Table 86. Panacea Biotec Limited Recent Development Table 87. Mycenax Biotech Inc. Company Information Table 88. Mycenax Biotech Inc. Business Overview Table 89. Mycenax Biotech Inc. Chronic Urticaria Or Hives Drug Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 90. Mycenax Biotech Inc. Chronic Urticaria Or Hives Drug Product Portfolio Table 91. Mycenax Biotech Inc. Recent Development Table 92. Mabtech Limited Company Information Table 93. Mabtech Limited Business Overview Table 94. Mabtech Limited Chronic Urticaria Or Hives Drug Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 95. Mabtech Limited Chronic Urticaria Or Hives Drug Product Portfolio Table 96. Mabtech Limited Recent Development Table 97. J Uriach Y Compania, S.A. Company Information Table 98. J Uriach Y Compania, S.A. Business Overview Table 99. J Uriach Y Compania, S.A. Chronic Urticaria Or Hives Drug Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 100. J Uriach Y Compania, S.A. Chronic Urticaria Or Hives Drug Product Portfolio Table 101. J Uriach Y Compania, S.A. Recent Development Table 102. GlaxoSmithKline Plc Company Information Table 103. GlaxoSmithKline Plc Business Overview Table 104. GlaxoSmithKline Plc Chronic Urticaria Or Hives Drug Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 105. GlaxoSmithKline Plc Chronic Urticaria Or Hives Drug Product Portfolio Table 106. GlaxoSmithKline Plc Recent Development Table 107. Genentech, Inc. Company Information Table 108. Genentech, Inc. Business Overview Table 109. Genentech, Inc. Chronic Urticaria Or Hives Drug Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 110. Genentech, Inc. Chronic Urticaria Or Hives Drug Product Portfolio Table 111. Genentech, Inc. Recent Development Table 112. Faes Farma, SA Company Information Table 113. Faes Farma, SA Business Overview Table 114. Faes Farma, SA Chronic Urticaria Or Hives Drug Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 115. Faes Farma, SA Chronic Urticaria Or Hives Drug Product Portfolio Table 116. Faes Farma, SA Recent Development Table 117. ELORAC, Inc. Company Information Table 118. ELORAC, Inc. Business Overview Table 119. ELORAC, Inc. Chronic Urticaria Or Hives Drug Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 120. ELORAC, Inc. Chronic Urticaria Or Hives Drug Product Portfolio Table 121. ELORAC, Inc. Recent Development Table 122. Biofrontera AG Company Information Table 123. Biofrontera AG Business Overview Table 124. Biofrontera AG Chronic Urticaria Or Hives Drug Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 125. Biofrontera AG Chronic Urticaria Or Hives Drug Product Portfolio Table 126. Biofrontera AG Recent Development Table 127. Key Raw Materials Table 128. Raw Materials Key Suppliers Table 129. Chronic Urticaria Or Hives Drug Distributors List Table 130. Chronic Urticaria Or Hives Drug Customers List Table 131. Research Programs/Design for This Report Table 132. Authors List of This Report Table 133. Secondary Sources Table 134. Primary Sources List of Figures Figure 1. Chronic Urticaria Or Hives Drug Product Image Figure 2. Global Chronic Urticaria Or Hives Drug Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Chronic Urticaria Or Hives Drug Sales Value (2021-2032) & (US$ Million) Figure 4. Global Chronic Urticaria Or Hives Drug Sales (2021-2032) & (W Units) Figure 5. Global Chronic Urticaria Or Hives Drug Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Chronic Urticaria Or Hives Drug Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. BF-Derm-1 Image Figure 10. GDC-0853 Image Figure 11. GSK-2646264 Image Figure 12. Bilastine Image Figure 13. Others Image Figure 14. Global Chronic Urticaria Or Hives Drug Sales Volume by Type (2021 VS 2025 VS 2032) & (W Units) Figure 15. Global Chronic Urticaria Or Hives Drug Sales Volume Share 2021 VS 2025 VS 2032 Figure 16. Global Chronic Urticaria Or Hives Drug Sales Volume Share by Type (2021-2032) Figure 17. Global Chronic Urticaria Or Hives Drug Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global Chronic Urticaria Or Hives Drug Sales Value Share 2021 VS 2025 VS 2032 Figure 19. Global Chronic Urticaria Or Hives Drug Sales Value Share by Type (2021-2032) Figure 20. Clinic Image Figure 21. Hospital Image Figure 22. Others Image Figure 23. Global Chronic Urticaria Or Hives Drug Sales Volume by Application (2021 VS 2025 VS 2032) & (W Units) Figure 24. Global Chronic Urticaria Or Hives Drug Sales Volume Share 2021 VS 2025 VS 2032 Figure 25. Global Chronic Urticaria Or Hives Drug Sales Volume Share by Application (2021-2032) Figure 26. Global Chronic Urticaria Or Hives Drug Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 27. Global Chronic Urticaria Or Hives Drug Sales Value Share 2021 VS 2025 VS 2032 Figure 28. Global Chronic Urticaria Or Hives Drug Sales Value Share by Application (2021-2032) Figure 29. Global Chronic Urticaria Or Hives Drug Sales by Region: 2021 VS 2025 VS 2032 (W Units) Figure 30. Global Chronic Urticaria Or Hives Drug Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 31. Global Chronic Urticaria Or Hives Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 32. Global Chronic Urticaria Or Hives Drug Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 33. North America Chronic Urticaria Or Hives Drug Sales Value (2021-2032) & (US$ Million) Figure 34. North America Chronic Urticaria Or Hives Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 35. Europe Chronic Urticaria Or Hives Drug Sales Value (2021-2032) & (US$ Million) Figure 36. Europe Chronic Urticaria Or Hives Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 37. Asia-Pacific Chronic Urticaria Or Hives Drug Sales Value (2021-2032) & (US$ Million) Figure 38. Asia-Pacific Chronic Urticaria Or Hives Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 39. South America Chronic Urticaria Or Hives Drug Sales Value (2021-2032) & (US$ Million) Figure 40. South America Chronic Urticaria Or Hives Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 41. Middle East & Africa Chronic Urticaria Or Hives Drug Sales Value (2021-2032) & (US$ Million) Figure 42. Middle East & Africa Chronic Urticaria Or Hives Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 43. USA Chronic Urticaria Or Hives Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. USA Chronic Urticaria Or Hives Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. USA Chronic Urticaria Or Hives Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. Canada Chronic Urticaria Or Hives Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. Canada Chronic Urticaria Or Hives Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. Canada Chronic Urticaria Or Hives Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Mexico Chronic Urticaria Or Hives Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Mexico Chronic Urticaria Or Hives Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Mexico Chronic Urticaria Or Hives Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. Germany Chronic Urticaria Or Hives Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. Germany Chronic Urticaria Or Hives Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. Germany Chronic Urticaria Or Hives Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. France Chronic Urticaria Or Hives Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. France Chronic Urticaria Or Hives Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. France Chronic Urticaria Or Hives Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. U.K. Chronic Urticaria Or Hives Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. U.K. Chronic Urticaria Or Hives Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. U.K. Chronic Urticaria Or Hives Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Italy Chronic Urticaria Or Hives Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Italy Chronic Urticaria Or Hives Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Italy Chronic Urticaria Or Hives Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Spain Chronic Urticaria Or Hives Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Spain Chronic Urticaria Or Hives Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Spain Chronic Urticaria Or Hives Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Russia Chronic Urticaria Or Hives Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Russia Chronic Urticaria Or Hives Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Russia Chronic Urticaria Or Hives Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Netherlands Chronic Urticaria Or Hives Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Netherlands Chronic Urticaria Or Hives Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Netherlands Chronic Urticaria Or Hives Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. Nordic Countries Chronic Urticaria Or Hives Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. Nordic Countries Chronic Urticaria Or Hives Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. Nordic Countries Chronic Urticaria Or Hives Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. China Chronic Urticaria Or Hives Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. China Chronic Urticaria Or Hives Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. China Chronic Urticaria Or Hives Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. Japan Chronic Urticaria Or Hives Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. Japan Chronic Urticaria Or Hives Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. Japan Chronic Urticaria Or Hives Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. South Korea Chronic Urticaria Or Hives Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. South Korea Chronic Urticaria Or Hives Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. South Korea Chronic Urticaria Or Hives Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. India Chronic Urticaria Or Hives Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. India Chronic Urticaria Or Hives Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. India Chronic Urticaria Or Hives Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Australia Chronic Urticaria Or Hives Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Australia Chronic Urticaria Or Hives Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Australia Chronic Urticaria Or Hives Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Southeast Asia Chronic Urticaria Or Hives Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Southeast Asia Chronic Urticaria Or Hives Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Southeast Asia Chronic Urticaria Or Hives Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Brazil Chronic Urticaria Or Hives Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Brazil Chronic Urticaria Or Hives Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Brazil Chronic Urticaria Or Hives Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Argentina Chronic Urticaria Or Hives Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Argentina Chronic Urticaria Or Hives Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Argentina Chronic Urticaria Or Hives Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Chile Chronic Urticaria Or Hives Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Chile Chronic Urticaria Or Hives Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Chile Chronic Urticaria Or Hives Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Colombia Chronic Urticaria Or Hives Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Colombia Chronic Urticaria Or Hives Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Colombia Chronic Urticaria Or Hives Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Peru Chronic Urticaria Or Hives Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Peru Chronic Urticaria Or Hives Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Peru Chronic Urticaria Or Hives Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Saudi Arabia Chronic Urticaria Or Hives Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Saudi Arabia Chronic Urticaria Or Hives Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Saudi Arabia Chronic Urticaria Or Hives Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Israel Chronic Urticaria Or Hives Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Israel Arabia Chronic Urticaria Or Hives Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Israel Arabia Chronic Urticaria Or Hives Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. UAE Chronic Urticaria Or Hives Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. UAE Chronic Urticaria Or Hives Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. UAE Chronic Urticaria Or Hives Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Turkey Chronic Urticaria Or Hives Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 119. Turkey Chronic Urticaria Or Hives Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 120. Turkey Chronic Urticaria Or Hives Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 121. Iran Chronic Urticaria Or Hives Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 122. Iran Chronic Urticaria Or Hives Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 123. Iran Chronic Urticaria Or Hives Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 124. Egypt Chronic Urticaria Or Hives Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 125. Egypt Chronic Urticaria Or Hives Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 126. Egypt Chronic Urticaria Or Hives Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 127. Chronic Urticaria Or Hives Drug Value Chain Figure 128. Manufacturing Cost Structure Figure 129. Chronic Urticaria Or Hives Drug Sales Mode & Process Figure 130. Direct Comparison with Distribution Share Figure 131. Distributors Profiles Figure 132. Years Considered Figure 133. Research Process Figure 134. Key Executives Interviewed

Scope & coverage.

Types
  • BF-Derm-1
  • GDC-0853
  • GSK-2646264
  • Bilastine
  • Others
Applications
  • Clinic
  • Hospital
  • Others
Companies covered
  • Novartis AG
  • Merck & Co., Inc.
  • AstraZeneca Plc
  • Panacea Biotec Limited
  • Mycenax Biotech Inc.
  • Mabtech Limited
  • J Uriach Y Compania, S.A.
  • GlaxoSmithKline Plc
  • Genentech, Inc.
  • Faes Farma, SA
  • ELORAC, Inc.
  • Biofrontera AG

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Chronic Urticaria Or Hives Drug Sales Value (2021-2032)
  4. 1.2.2 Global Chronic Urticaria Or Hives Drug Sales Volume (2021-2032)
  5. 1.2.3 Global Chronic Urticaria Or Hives Drug Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Chronic Urticaria Or Hives Drug Market Dynamics
  1. 2.1 Chronic Urticaria Or Hives Drug Industry Trends
  2. 2.2 Chronic Urticaria Or Hives Drug Industry Drivers
  3. 2.3 Chronic Urticaria Or Hives Drug Industry Opportunities and Challenges
  4. 2.4 Chronic Urticaria Or Hives Drug Industry Restraints
3 Chronic Urticaria Or Hives Drug Market by Company
  1. 3.1 Global Chronic Urticaria Or Hives Drug Company Revenue Ranking in 2025
  2. 3.2 Global Chronic Urticaria Or Hives Drug Revenue by Company (2021-2026)
  3. 3.3 Global Chronic Urticaria Or Hives Drug Sales Volume by Company (2021-2026)
  4. 3.4 Global Chronic Urticaria Or Hives Drug Average Price by Company (2021-2026)
  5. 3.5 Global Chronic Urticaria Or Hives Drug Company Ranking (2024-2026)
  6. 3.6 Global Chronic Urticaria Or Hives Drug Company Manufacturing Base and Headquarters
  7. 3.7 Global Chronic Urticaria Or Hives Drug Company Product Type and Application
  8. 3.8 Global Chronic Urticaria Or Hives Drug Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Chronic Urticaria Or Hives Drug Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Chronic Urticaria Or Hives Drug Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Chronic Urticaria Or Hives Drug Market by Type
  1. 4.1 Chronic Urticaria Or Hives Drug Type Introduction
  2. 4.1.1 BF-Derm-1
  3. 4.1.2 GDC-0853
  4. 4.1.3 GSK-2646264
  5. 4.1.4 Bilastine
  6. 4.1.5 Others
  7. 4.2 Global Chronic Urticaria Or Hives Drug Sales Volume by Type
  8. 4.2.1 Global Chronic Urticaria Or Hives Drug Sales Volume by Type (2021 VS 2025 VS 2032)
  9. 4.2.2 Global Chronic Urticaria Or Hives Drug Sales Volume by Type (2021-2032)
  10. 4.2.3 Global Chronic Urticaria Or Hives Drug Sales Volume Share by Type (2021-2032)
  11. 4.3 Global Chronic Urticaria Or Hives Drug Sales Value by Type
  12. 4.3.1 Global Chronic Urticaria Or Hives Drug Sales Value by Type (2021 VS 2025 VS 2032)
  13. 4.3.2 Global Chronic Urticaria Or Hives Drug Sales Value by Type (2021-2032)
  14. 4.3.3 Global Chronic Urticaria Or Hives Drug Sales Value Share by Type (2021-2032)
5 Chronic Urticaria Or Hives Drug Market by Application
  1. 5.1 Chronic Urticaria Or Hives Drug Application Introduction
  2. 5.1.1 Clinic
  3. 5.1.2 Hospital
  4. 5.1.3 Others
  5. 5.2 Global Chronic Urticaria Or Hives Drug Sales Volume by Application
  6. 5.2.1 Global Chronic Urticaria Or Hives Drug Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Chronic Urticaria Or Hives Drug Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Chronic Urticaria Or Hives Drug Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Chronic Urticaria Or Hives Drug Sales Value by Application
  10. 5.3.1 Global Chronic Urticaria Or Hives Drug Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Chronic Urticaria Or Hives Drug Sales Value by Application (2021-2032)
  12. 5.3.3 Global Chronic Urticaria Or Hives Drug Sales Value Share by Application (2021-2032)
6 Chronic Urticaria Or Hives Drug Regional Sales and Value Analysis
  1. 6.1 Global Chronic Urticaria Or Hives Drug Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Chronic Urticaria Or Hives Drug Sales by Region (2021-2032)
  3. 6.2.1 Global Chronic Urticaria Or Hives Drug Sales by Region: 2021-2026
  4. 6.2.2 Global Chronic Urticaria Or Hives Drug Sales by Region (2027-2032)
  5. 6.3 Global Chronic Urticaria Or Hives Drug Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Chronic Urticaria Or Hives Drug Sales Value by Region (2021-2032)
  7. 6.4.1 Global Chronic Urticaria Or Hives Drug Sales Value by Region: 2021-2026
  8. 6.4.2 Global Chronic Urticaria Or Hives Drug Sales Value by Region (2027-2032)
  9. 6.5 Global Chronic Urticaria Or Hives Drug Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Chronic Urticaria Or Hives Drug Sales Value (2021-2032)
  12. 6.6.2 North America Chronic Urticaria Or Hives Drug Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Chronic Urticaria Or Hives Drug Sales Value (2021-2032)
  15. 6.7.2 Europe Chronic Urticaria Or Hives Drug Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Chronic Urticaria Or Hives Drug Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Chronic Urticaria Or Hives Drug Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Chronic Urticaria Or Hives Drug Sales Value (2021-2032)
  21. 6.9.2 South America Chronic Urticaria Or Hives Drug Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Chronic Urticaria Or Hives Drug Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Chronic Urticaria Or Hives Drug Sales Value Share by Country, 2025 VS 2032
7 Chronic Urticaria Or Hives Drug Country-level Sales and Value Analysis
  1. 7.1 Global Chronic Urticaria Or Hives Drug Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Chronic Urticaria Or Hives Drug Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Chronic Urticaria Or Hives Drug Sales by Country (2021-2032)
  4. 7.3.1 Global Chronic Urticaria Or Hives Drug Sales by Country (2021-2026)
  5. 7.3.2 Global Chronic Urticaria Or Hives Drug Sales by Country (2027-2032)
  6. 7.4 Global Chronic Urticaria Or Hives Drug Sales Value by Country (2021-2032)
  7. 7.4.1 Global Chronic Urticaria Or Hives Drug Sales Value by Country (2021-2026)
  8. 7.4.2 Global Chronic Urticaria Or Hives Drug Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Chronic Urticaria Or Hives Drug Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Chronic Urticaria Or Hives Drug Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Chronic Urticaria Or Hives Drug Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Chronic Urticaria Or Hives Drug Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Chronic Urticaria Or Hives Drug Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Chronic Urticaria Or Hives Drug Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Chronic Urticaria Or Hives Drug Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Chronic Urticaria Or Hives Drug Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Chronic Urticaria Or Hives Drug Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Chronic Urticaria Or Hives Drug Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Chronic Urticaria Or Hives Drug Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Chronic Urticaria Or Hives Drug Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Chronic Urticaria Or Hives Drug Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Chronic Urticaria Or Hives Drug Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Chronic Urticaria Or Hives Drug Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Chronic Urticaria Or Hives Drug Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Chronic Urticaria Or Hives Drug Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Chronic Urticaria Or Hives Drug Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Chronic Urticaria Or Hives Drug Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Chronic Urticaria Or Hives Drug Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Chronic Urticaria Or Hives Drug Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Chronic Urticaria Or Hives Drug Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Chronic Urticaria Or Hives Drug Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Chronic Urticaria Or Hives Drug Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Chronic Urticaria Or Hives Drug Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Chronic Urticaria Or Hives Drug Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Chronic Urticaria Or Hives Drug Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Chronic Urticaria Or Hives Drug Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Chronic Urticaria Or Hives Drug Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Chronic Urticaria Or Hives Drug Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Chronic Urticaria Or Hives Drug Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Chronic Urticaria Or Hives Drug Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Chronic Urticaria Or Hives Drug Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Chronic Urticaria Or Hives Drug Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Chronic Urticaria Or Hives Drug Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Chronic Urticaria Or Hives Drug Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Chronic Urticaria Or Hives Drug Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Chronic Urticaria Or Hives Drug Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Chronic Urticaria Or Hives Drug Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Chronic Urticaria Or Hives Drug Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Chronic Urticaria Or Hives Drug Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Chronic Urticaria Or Hives Drug Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Chronic Urticaria Or Hives Drug Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Chronic Urticaria Or Hives Drug Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Chronic Urticaria Or Hives Drug Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Chronic Urticaria Or Hives Drug Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Chronic Urticaria Or Hives Drug Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Chronic Urticaria Or Hives Drug Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Chronic Urticaria Or Hives Drug Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Chronic Urticaria Or Hives Drug Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Chronic Urticaria Or Hives Drug Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Chronic Urticaria Or Hives Drug Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Chronic Urticaria Or Hives Drug Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Chronic Urticaria Or Hives Drug Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Chronic Urticaria Or Hives Drug Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Chronic Urticaria Or Hives Drug Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Chronic Urticaria Or Hives Drug Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Chronic Urticaria Or Hives Drug Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Chronic Urticaria Or Hives Drug Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Chronic Urticaria Or Hives Drug Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Chronic Urticaria Or Hives Drug Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Chronic Urticaria Or Hives Drug Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Chronic Urticaria Or Hives Drug Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Chronic Urticaria Or Hives Drug Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Chronic Urticaria Or Hives Drug Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Chronic Urticaria Or Hives Drug Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Chronic Urticaria Or Hives Drug Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Chronic Urticaria Or Hives Drug Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Chronic Urticaria Or Hives Drug Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Chronic Urticaria Or Hives Drug Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Chronic Urticaria Or Hives Drug Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Chronic Urticaria Or Hives Drug Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Chronic Urticaria Or Hives Drug Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Chronic Urticaria Or Hives Drug Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Chronic Urticaria Or Hives Drug Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Chronic Urticaria Or Hives Drug Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Chronic Urticaria Or Hives Drug Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Chronic Urticaria Or Hives Drug Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Chronic Urticaria Or Hives Drug Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Chronic Urticaria Or Hives Drug Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Chronic Urticaria Or Hives Drug Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Chronic Urticaria Or Hives Drug Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Chronic Urticaria Or Hives Drug Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Chronic Urticaria Or Hives Drug Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Novartis AG
  2. 8.1.1 Novartis AG Company Information
  3. 8.1.2 Novartis AG Business Overview
  4. 8.1.3 Novartis AG Chronic Urticaria Or Hives Drug Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Novartis AG Chronic Urticaria Or Hives Drug Product Portfolio
  6. 8.1.5 Novartis AG Recent Developments
  7. 8.2 Merck & Co., Inc.
  8. 8.2.1 Merck & Co., Inc. Company Information
  9. 8.2.2 Merck & Co., Inc. Business Overview
  10. 8.2.3 Merck & Co., Inc. Chronic Urticaria Or Hives Drug Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Merck & Co., Inc. Chronic Urticaria Or Hives Drug Product Portfolio
  12. 8.2.5 Merck & Co., Inc. Recent Developments
  13. 8.3 AstraZeneca Plc
  14. 8.3.1 AstraZeneca Plc Company Information
  15. 8.3.2 AstraZeneca Plc Business Overview
  16. 8.3.3 AstraZeneca Plc Chronic Urticaria Or Hives Drug Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 AstraZeneca Plc Chronic Urticaria Or Hives Drug Product Portfolio
  18. 8.3.5 AstraZeneca Plc Recent Developments
  19. 8.4 Panacea Biotec Limited
  20. 8.4.1 Panacea Biotec Limited Company Information
  21. 8.4.2 Panacea Biotec Limited Business Overview
  22. 8.4.3 Panacea Biotec Limited Chronic Urticaria Or Hives Drug Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Panacea Biotec Limited Chronic Urticaria Or Hives Drug Product Portfolio
  24. 8.4.5 Panacea Biotec Limited Recent Developments
  25. 8.5 Mycenax Biotech Inc.
  26. 8.5.1 Mycenax Biotech Inc. Company Information
  27. 8.5.2 Mycenax Biotech Inc. Business Overview
  28. 8.5.3 Mycenax Biotech Inc. Chronic Urticaria Or Hives Drug Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Mycenax Biotech Inc. Chronic Urticaria Or Hives Drug Product Portfolio
  30. 8.5.5 Mycenax Biotech Inc. Recent Developments
  31. 8.6 Mabtech Limited
  32. 8.6.1 Mabtech Limited Company Information
  33. 8.6.2 Mabtech Limited Business Overview
  34. 8.6.3 Mabtech Limited Chronic Urticaria Or Hives Drug Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Mabtech Limited Chronic Urticaria Or Hives Drug Product Portfolio
  36. 8.6.5 Mabtech Limited Recent Developments
  37. 8.7 J Uriach Y Compania, S.A.
  38. 8.7.1 J Uriach Y Compania, S.A. Company Information
  39. 8.7.2 J Uriach Y Compania, S.A. Business Overview
  40. 8.7.3 J Uriach Y Compania, S.A. Chronic Urticaria Or Hives Drug Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 J Uriach Y Compania, S.A. Chronic Urticaria Or Hives Drug Product Portfolio
  42. 8.7.5 J Uriach Y Compania, S.A. Recent Developments
  43. 8.8 GlaxoSmithKline Plc
  44. 8.8.1 GlaxoSmithKline Plc Company Information
  45. 8.8.2 GlaxoSmithKline Plc Business Overview
  46. 8.8.3 GlaxoSmithKline Plc Chronic Urticaria Or Hives Drug Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 GlaxoSmithKline Plc Chronic Urticaria Or Hives Drug Product Portfolio
  48. 8.8.5 GlaxoSmithKline Plc Recent Developments
  49. 8.9 Genentech, Inc.
  50. 8.9.1 Genentech, Inc. Company Information
  51. 8.9.2 Genentech, Inc. Business Overview
  52. 8.9.3 Genentech, Inc. Chronic Urticaria Or Hives Drug Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Genentech, Inc. Chronic Urticaria Or Hives Drug Product Portfolio
  54. 8.9.5 Genentech, Inc. Recent Developments
  55. 8.10 Faes Farma, SA
  56. 8.10.1 Faes Farma, SA Company Information
  57. 8.10.2 Faes Farma, SA Business Overview
  58. 8.10.3 Faes Farma, SA Chronic Urticaria Or Hives Drug Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Faes Farma, SA Chronic Urticaria Or Hives Drug Product Portfolio
  60. 8.10.5 Faes Farma, SA Recent Developments
  61. 8.11 ELORAC, Inc.
  62. 8.11.1 ELORAC, Inc. Company Information
  63. 8.11.2 ELORAC, Inc. Business Overview
  64. 8.11.3 ELORAC, Inc. Chronic Urticaria Or Hives Drug Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 ELORAC, Inc. Chronic Urticaria Or Hives Drug Product Portfolio
  66. 8.11.5 ELORAC, Inc. Recent Developments
  67. 8.12 Biofrontera AG
  68. 8.12.1 Biofrontera AG Company Information
  69. 8.12.2 Biofrontera AG Business Overview
  70. 8.12.3 Biofrontera AG Chronic Urticaria Or Hives Drug Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 Biofrontera AG Chronic Urticaria Or Hives Drug Product Portfolio
  72. 8.12.5 Biofrontera AG Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Chronic Urticaria Or Hives Drug Value Chain Analysis
  2. 9.1.1 Chronic Urticaria Or Hives Drug Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Chronic Urticaria Or Hives Drug Sales Mode & Process
  6. 9.2 Chronic Urticaria Or Hives Drug Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Chronic Urticaria Or Hives Drug Distributors
  9. 9.2.3 Chronic Urticaria Or Hives Drug Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst